| abstract |
The present invention relates to acyl coenzyme A: a novel compound that is an inhibitor of diacylglycerol acyltransferase 1 (DGAT-1), a pharmaceutical composition containing the same, a preparation method thereof, and obesity, obesity related disorders, hypertriglyceridemia, hyperlipoproteinemia, Associated with or associated with DGAT-1 dysfunction, including but not limited to kilomicronemia, dyslipidemia, non-alcoholic steatohepatitis, diabetes, insulin resistance, metabolic syndrome, hepatitis C virus infection, and acne or other skin disorders Or to the use thereof in therapy for the prevention or treatment of a disease in which modulation of DGAT-1 activity may have therapeutic benefit. |